Fax: (734) 763-7370
Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases—Equivalent efficacy, less toxicity, more convenient†
A subset analysis of Radiation Therapy Oncology Group trial 97-14
Version of Record online: 16 NOV 2012
Copyright © 2012 American Cancer Society
Volume 119, Issue 4, pages 888–896, 15 February 2013
How to Cite
Howell, D. D., James, J. L., Hartsell, W. F., Suntharalingam, M., Machtay, M., Suh, J. H., Demas, W. F., Sandler, H. M., Kachnic, L. A. and Berk, L. B. (2013), Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases—Equivalent efficacy, less toxicity, more convenient. Cancer, 119: 888–896. doi: 10.1002/cncr.27616
The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
- Issue online: 4 FEB 2013
- Version of Record online: 16 NOV 2012
- Manuscript Accepted: 14 MAR 2012
- Manuscript Revised: 13 MAR 2012
- Manuscript Received: 13 FEB 2012
- radiation oncology;
- bone metastases;
- palliative care;
- pain management;
- supportive care;
- single-fraction radiation;
- stereotactic radiation therapy;
- spine malignancy;
- late effects
The Radiation Therapy Oncology Group (RTOG) trial 97-14 revealed no difference between radiation delivered for painful bone metastases at a dose of 8 gray (Gy) in 1 fraction (single-fraction radiotherapy [SFRT]) and 30 Gy in 10 fractions (multifraction radiotherapy [MFRT]) in pain relief or narcotic use 3 months after randomization. SFRT for painful vertebral bone metastases (PVBM) has not been well accepted, possibly because of concerns about efficacy and toxicity. In the current study, the authors evaluated the subset of patients that was treated specifically for patients with PVBM.
PVBM included the cervical, thoracic, and/or lumbar spine regions. Among patients with PVBM, differences in retreatment rates and in pain relief, narcotic use, and toxicity 3 months after randomization were evaluated.
Of 909 eligible patients, 235 (26%) had PVBM. Patients with and without PVBM differed in terms of the percentage of men (55% vs 47%, respectively; P = .03) and the proportion of patients with multiple painful sites (57% vs 38%, respectively; P < .01). Among those with PVBM, more patients who received MFRT had multiple sites treated (65% vs 49% for MFRT vs SFRT, respectively; P = .02). There were no statistically significant treatment differences in terms of pain relief (62% vs 70% for MFRT vs SFRT, respectively; P = .59) or freedom from narcotic use (24% vs 27%, respectively; P = .76) at 3 months. Significant differences in acute grade 2 through 4 toxicity (20% vs 10% for MFRT vs SFRT, respectively; P = .01) and acute grade 2 through 4 gastrointestinal toxicity (14% vs 6%, respectively; P = .01) were observed at 3 months, with lower toxicities seen in the patients treated with SFRT. Late toxicity was rare. No myelopathy was recorded. SFRT produced higher 3-year retreatment rates (5% vs 15%; P = .01).
Results for the subset of patients with PVBM in the RTOG 94-17 randomized controlled trial were comparable to those for the entire population. SFRT produced less acute toxicity and a higher rate of retreatment than MFRT. SFRT and MFRT resulted in comparable pain relief and narcotic use at 3 months. Cancer 2013. © 2012 American Cancer Society.